bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition

bit.bio, the company coding human cells for novel cures, will showcase recent data and important applications of its new portfolio of ioCRISPR-Ready Cells at the Society for Laboratory Automation and Screening (SLAS) conference. SLAS will take place from 3-7 February 2024 at the Boston Convention and Exhibition Center. 

With our ioCRISPR-Ready Cells, we're providing scientists with a powerful functional genomics tool to study any gene of interest in a defined human iPSC-derived cell system. Gene knockout experiments such as CRISPR screens that would previously require substantial time and specialised skills can now be undertaken in weeks by scientists with all levels of experience. We are excited to share these data at SLAS and to discuss the tremendous potential that this product range offers.

Dr. Farah Patell-Socha, VP research products, bit.bio

At SLAS, the team will present posters on two ioCRISPR-Ready Cells products, confirming their ease of use and that they generate readouts within days using a simple protocol for cell maturation and guide RNA delivery: 

  • CRISPR-Ready ioGlutamatergic Neurons: a functional genomics tool to easily generate disease-specific models for drug discovery and development. Poster Session C, Tuesday 6 February, 12-1pm. Track: Assay Development and Screening. This product was launched by bit.bio in October 2023
  • CRISPR knockout screening for drug target identification and validation using CRISPR-Ready ioMicroglia. Poster Session D, Tuesday 6 February, 2-3 pm. Track: Cellular Technologies. This is the next product in the ioCRISPR-Ready Cells range that will launch in 2024. 

ioCRISPR-Ready Cells are iPSC-derived human cells containing a constitutively-expressed Cas9 nuclease. They arrive ready to use and with simple protocols, allowing high gene knockout efficiencies and functional experimental readouts in a physiologically relevant cellular model in days, significantly reducing experimental timelines. ioCRISPR-Ready Cells can also be scaled to high-throughput pooled or arrayed CRISPR screens. Potential applications include functional genomics, disease model generation, drug target identification and fundamental human biology research. 

All bit.bio ioCellsTM products, including ioCRISPR-Ready Cells, are precision reprogrammed using bit.bio’s opti-oxTM technology. As such, they are defined as human cells that have inherent experimental scalability, offer unparallelled consistency and are simple to handle and culture.

At SLAS, bit.bio will host an expert panel discussion on the vital role of functional genomics in early drug discovery. The panel discussion will cover the urgent need for predictive models in target identification, specific challenges across different fields such as oncology and neuroscience, and the trade-offs involved in using different cell models and different techniques for CRISPR screening. 

  • Speakers: 
    • Rob Howes, PhD - Head of Discovery Sciences UK at Charles River Laboratories
    • Davide Gianni, PhD - Senior Director Functional Genomics, Discovery Sciences, BioPharmaceuticals R&D at AstraZeneca
    • Josh Tycko, PhD - Research Fellow in Neurobiology at Harvard Medical School
    • Ann Byrne, PhD - Functional Genomics at bit.bio
  • Date and time: Tuesday 3rd February 8:30 am - 10:00 am ET, room 104B 

CRISPR-Ready ioGlutamatergic NeuronsTM have been shortlisted for the SelectScience “Best New Drug Discovery & Development Product”. The winner will be announced at SLAS. 

The bit.bio stand and members of the team will be at location 881 in the exhibition hall. 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Society for Laboratory Automation and Screening (SLAS). (2024, February 05). bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition. News-Medical. Retrieved on April 17, 2024 from https://www.news-medical.net/news/20240205/bitbio-to-showcase-its-ioCRISPR-Ready-CellsTM-products-at-the-SLAS-2024-international-conference-and-exhibition.aspx.

  • MLA

    Society for Laboratory Automation and Screening (SLAS). "bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition". News-Medical. 17 April 2024. <https://www.news-medical.net/news/20240205/bitbio-to-showcase-its-ioCRISPR-Ready-CellsTM-products-at-the-SLAS-2024-international-conference-and-exhibition.aspx>.

  • Chicago

    Society for Laboratory Automation and Screening (SLAS). "bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition". News-Medical. https://www.news-medical.net/news/20240205/bitbio-to-showcase-its-ioCRISPR-Ready-CellsTM-products-at-the-SLAS-2024-international-conference-and-exhibition.aspx. (accessed April 17, 2024).

  • Harvard

    Society for Laboratory Automation and Screening (SLAS). 2024. bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition. News-Medical, viewed 17 April 2024, https://www.news-medical.net/news/20240205/bitbio-to-showcase-its-ioCRISPR-Ready-CellsTM-products-at-the-SLAS-2024-international-conference-and-exhibition.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pharmatech: The Art of AI-Driven Drug Design with Exscientia